In one of the largest rounds in Europe, CureVac GmbH, a Tübingen, Germany-based clinical stage biopharmaceutical company developing a new class of therapies and vaccines based on mRNA, has completed an €80m financing round with dievini Hopp BioTech Holding.
The company intends to use the proceeds to advance the development of its two lead RNActive® cancer vaccines against prostate cancer and non-small cell lung cancer (NSCLC), respectively, as well as to intensify the development of its prophylactic vaccines and adjuvants for infectious diseases.
Led by CEO Ingmar Hoerr, Ph.D., and Friedrich von Bohlen, Ph.D., chairman of the board of directors and managing partner at dievini Hopp Biotech, CureVac uses its RNA technology platform to develop novel therapeutic mRNA vaccines (RNActive) for cancer and prophylactic vaccines for infectious diseases and adjuvants based on long, non-coding RNAs (RNAdjuvant) for enhancing the immune response of other vaccines.
The company has completed Phase 1/2a studies with its RNActive cancer vaccines in prostate cancer and non-small cell lung cancer (NSCLC). In addition to developing its own pipeline, CureVac is collaborating with Sanofi Pasteur and DARPA on a $33 million project for the development of therapeutic and prophylactic vaccines in infectious diseases utilizing its RNActive technology platform.